BACKGROUND/AIMS: Aim of our study was to analyze fibrosis progression after liver transplantation (OLT) in hepatitis C virus (HCV)-infected patients based on protocol liver biopsies and to identify risk factors, which may play a role in the development of severe fibrosis stages. METHODS: One hundred and eighty-three liver graft recipients who had a histological follow-up evaluation of 1 year after OLT were analyzed. Overall 1039 protocol liver biopsies were performed after 1-, 3-, 5-, 7- and 10 years and staged according to the Scheuer score. RESULTS: The fibrosis progression rate was not linear. The fibrosis scores were 1.2 after one, 1.7 after three, 1.9 after five, 2.1 after 7 and 2.2 after 10 years. The 39 recipients with fibrosis stages 3 or 4 in the 1-year biopsy had a significantly reduced survival rate, while fibrosis stage 0-2 indicated excellent survival. Independent risk factors for progression of fibrosis at 1 year were HCV genotype 1 and 4 (P=0.01) and donor age>33 years (P=0.01), whereas risk factors for development of cirrhosis (30/183 recipients (16%)) were donor age (P=0.002) and multiple steroid pulses (P=0.05). CONCLUSIONS: These data provide information on the course of recurrent hepatitis C and may be helpful to individualize the treatment of transplanted patients.
BACKGROUND/AIMS: Aim of our study was to analyze fibrosis progression after liver transplantation (OLT) in hepatitis C virus (HCV)-infectedpatients based on protocol liver biopsies and to identify risk factors, which may play a role in the development of severe fibrosis stages. METHODS: One hundred and eighty-three liver graft recipients who had a histological follow-up evaluation of 1 year after OLT were analyzed. Overall 1039 protocol liver biopsies were performed after 1-, 3-, 5-, 7- and 10 years and staged according to the Scheuer score. RESULTS: The fibrosis progression rate was not linear. The fibrosis scores were 1.2 after one, 1.7 after three, 1.9 after five, 2.1 after 7 and 2.2 after 10 years. The 39 recipients with fibrosis stages 3 or 4 in the 1-year biopsy had a significantly reduced survival rate, while fibrosis stage 0-2 indicated excellent survival. Independent risk factors for progression of fibrosis at 1 year were HCV genotype 1 and 4 (P=0.01) and donor age>33 years (P=0.01), whereas risk factors for development of cirrhosis (30/183 recipients (16%)) were donor age (P=0.002) and multiple steroid pulses (P=0.05). CONCLUSIONS: These data provide information on the course of recurrent hepatitis C and may be helpful to individualize the treatment of transplanted patients.
Authors: Jennifer E Layden; Scott J Cotler; Shellee A Grim; Michael J Fischer; Michael R Lucey; Nina M Clark Journal: Transplantation Date: 2012-02-27 Impact factor: 4.939
Authors: Tanya R Flohr; Hugo Bonatti; Tjasa Hranjec; Doug S Keith; Peter I Lobo; Sean C Kumer; Timothy M Schmitt; Robert G Sawyer; Timothy L Pruett; John P Roberts; Kenneth L Brayman Journal: J Surg Res Date: 2011-11-19 Impact factor: 2.192
Authors: G Tsoulfas; I Goulis; D Giakoustidis; E Akriviadis; P Agorastou; G Imvrios; V Papanikolaou Journal: Hippokratia Date: 2009-10 Impact factor: 0.471
Authors: Russell M Yee; Mandeep S Lehil; Catherine Rongey; Hui Shen; Myrna L Cozen; Alexander Monto; James C Ryan Journal: Clin Vaccine Immunol Date: 2013-02-06